Our Programs

HDAC Inhibitor

DRUG CANDIDATE

Pracinostat HDAC Inhibitor

INDICATION / COMBINATION

Acute Myeloid Leukemia

Unfit for intensive chemotherapy
Vidaza® (azacitidine)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
INDICATION / COMBINATION

Myelodysplastic Syndrome

High & very high risk
Vidaza® (azacitidine)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal

PI3K Delta Inhibitor

DRUG CANDIDATE

ME-401 PI3K Delta Inhibitor

INDICATION / COMBINATION

CLL & Follicular Lymphoma

Relapsed/refractory
Single Agent
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
INDICATION / COMBINATION

Indolent Lymphoma & DLBCL

Relapsed/refractory
Rituxan® (rituximab)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal

Selective CDK Inhibitor

DRUG CANDIDATE

Voruciclib CDK Inhibitor

INDICATION / COMBINATION

Chronic Lymphocytic Leukemia

Relapsed/refractory del(17p)
Venclexta™ (venetoclax)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal

Mitochondrial Inhibitor

DRUG CANDIDATE

ME-344 Mitochondrial Inhibitor

INDICATION / COMBINATION

HER2-Negative Breast

Treatment-naïve, early stage
Avastin® (bevacizumab)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal